×

In Crowded Field Of Psychedelic Startups, Filament CEO Makes Case For ‘Natural’ Drugs

Benjamin Lightburn, CEO of Filament, is pictured.

A recent boom in psychedelic research has given way to a bumper crop of startups seeking to harness the potential of mind-altering drugs for treating…

Starting at $3.50/week.

Subscribe Today